Results 61 to 70 of about 37,443 (297)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Experimental dataset of masonry prisms with hollow concrete blocks

Data in Brief
The uniaxial compressive strength is a main parameter to be considered in design of masonry structures, particularly due to gravitational loads. This dataset collection comprises test on various masonry prisms made of hollow concrete blocks. These prisms
Jorge H. Chávez-Gómez, José Álvarez-Pérez, Milena Mesa-Lavista, Ramón García-Cedeño, Franco A. Carpio-Santamaría, G. Fajardo-San-Miguel, Fabiola D. Yépez-Rincón   +6 more
doaj   +1 more source

Flow around triangular prisms with varying vertex angle at low Reynolds numbers

The present work investigates the unsteady flow around triangular prisms with vertex angles of 30°,45°,60°, and 90° for shedding Reynolds number between 50 and 150. The numerical simulations of flow around triangular prisms at different vertex angles and
Khan, Majid Hassan, Khan, Hamid Hassan
core   +1 more source

Refractions and prisms for the 24 participants.

, 2015
BO and BI refers to prisms base-out and base-in, BU and BD refers to prisms base-up and base-down.
Wolfgang Jaschinski (802814), Roland Joos (802813), Volkhard Schroth (802812)   +2 more
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

An intervention to promote patient participation and self-management in long term conditions: development and feasibility testing

BMC Health Services Research, 2010
Background There is worldwide interest in managing the global burden of long-term conditions. Current health policy places emphasis on self-management and supporting patient participation as ways of improving patient outcomes and reducing costs. However,
Chew-Graham Carolyn, Bower Peter, Blakeman Tom, Protheroe Joanne, Kennedy Anne   +4 more
doaj   +1 more source

Transient flows past arrays of yawed finite prisms [PDF]

, 2017
Transient flows past arrays of yawed finite-length prisms in tandem and staggered arrangements are simulated. Large eddy simulation method is employed to characterize spatial and temporal characteristics of flows in the vicinity of prisms.
Bashar Attiya, Alparslan Oztekin, I-Han Liu, Oztekin, Alparslan, Liu, I-Han, Attiya, Bashar   +5 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source